SpectraCure AB Quarterly Report (1 July to 30 September) 2019

Third quarter (1 July – 30 September 2019)

• Other income amounted to TSEK 692 (215).
• Profit after tax amounted to TSEK -3 054 (-1 922).
• Corresponding to SEK -0,04 (-0,03) kr per share before and after diluted earnings.
• Operating cash flow was TSEK -3 072 (-2 640).
• Cash as of 30 September amounted to TSEK 25 421 (2 185) TSEK.
• Equity ratio: 81 (85)%.

1 January – 30 September 2019

• Other income amounted to TSEK 2 005 (902).
• Profit after tax amounted to TSEK -9 979 (-8 572).
• Corresponding to SEK -0,12 (-0,13) kr per share before and after diluted earnings.
• Operating cash flow was TSEK -6 648 (-7 058).

For further information, please contact:
 

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46(0) 8 503 000 50 

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on November 12th, 2019 at 2 p m.

SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region.

Tags: